Results 21 to 30 of about 3,200 (166)

The “Immunoscore” in rectal cancer: could we search quality beyond quantity of life? [PDF]

Oncotarget, 2022
Because of the function and anatomical environment of the rectum, therapeutic strategies for local advanced rectal cancer (LARC) must deal with two challenging stressors that are a high-risk of local and distal recurrences and a high-risk of poor quality of life (QoL).
Kirilovsky, Amos, El Sissy, Carine, Zeitoun, Guy, Marliot, Florence, Haicheur, Nacilla, Lagorce-Pagès, Christine, Taieb, Julien, Karoui, Mehdi, Custers, Petra, Dizdarevic, Edina, Iseas, Soledad, Hansen, Torben, Jensen, Lars, Beets, Geerard, Gérard, Jean, Castillo-Martin, Mireia, Figueiredo, Nuno, Habr-Gama, Angelita, Perez, Rodrigo, Galon, Jérôme, Pagès, Franck   +20 more
openaire   +5 more sources

Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours [PDF]

The Journal of Pathology, 2013
AbstractThe American Joint Committee on Cancer/Union Internationale Contre le Cancer (AJCC/UICC) TNM staging system provides the most reliable guidelines for the routine prognostication and treatment of colorectal carcinoma. This traditional tumour staging summarizes data on tumour burden (T), the presence of cancer cells in draining and regional lymph
Galon, J., Mlecnik, B., Bindea, G., Angell, H.K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., Nagtegaal, I.D., Nagtegaal, I.D., Palmqvist, R., Masucci, G.V., Botti, G., Tatangelo, F., Delrio, P., Maio, M., Laghi, L., Grizzi, F., Asslaber, M., D'Arrigo, C., Vidal-Vanaclocha, F., Zavadova, E., Chouchane, L., Ohashi, P.S., Hafezi-Bakhtiari, S., Wouters, B.G., Roehrl, M., Nguyen, L, Kawakami, Y., Hazama, S., Okuno, K., Ogino, S., Gibbs, P., Waring, P., Sato, N., Torigoe, T., Itoh, K., Patel, P.S., Shukla, S.N., Wang, Y., Kopetz, S., Sinicrope, F.A., Scripcariu, V., Ascierto, P.A., Marincola, F.M., Fox, B.A., Pages, F.   +48 more
openaire   +7 more sources

Prognostic Value of Immunoscore in Colorectal Carcinomas

International Journal of Surgical Pathology, 2022
Abstract Background Immunoscore (IS), based on the evaluation of CD3 + and CD8 + densities in the center of the tumor (CT) and its invasive margin (IM), is currently considered as a potential prognostic factor, particularly in colorectal carcinomas (CRC). In the current study, we aimed to assess the prognostic value of IS in CRC stage I to IV,
Helal Imen, Hmidi Amira, Khanchel Fatma, Jouini Raja, Sabbah Mariem, Zaafouri Haithem, Ben Brahim Ehsene, Chadlidebbiche Aschraf   +7 more
openaire   +2 more sources

No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study

OncoImmunology, 2020
The multicenter international Society for Immunotherapy of Cancer (SITC) study of the consensus Immunoscore demonstrated the prediction of survival and response to chemotherapy in 763 Stage III colon cancer (CC) patients.
Paolo A. Ascierto, Francesco M. Marincola, Bernard A. Fox, Jérôme Galon   +3 more
doaj   +1 more source

Multi-Institutional Evaluation of Pathologists’ Assessment Compared to Immunoscore

Cancers, 2023
Background: The Immunoscore (IS) is a quantitative digital pathology assay that evaluates the immune response in cancer patients. This study reports on the reproducibility of pathologists’ visual assessment of CD3+- and CD8+-stained colon tumors, compared to IS quantification.
Joseph Willis, Robert A. Anders, Toshihiko Torigoe, Yoshihiko Hirohashi, Carlo Bifulco, Inti Zlobec, Bernhard Mlecnik, Sandra Demaria, Won-Tak Choi, Pavel Dundr, Fabiana Tatangelo, Annabella Di Mauro, Pamela Baldin, Gabriela Bindea, Florence Marliot, Nacilla Haicheur, Tessa Fredriksen, Amos Kirilovsky, Bénédicte Buttard, Angela Vasaturo, Lucie Lafontaine, Pauline Maby, Carine El Sissy, Assia Hijazi, Amine Majdi, Christine Lagorce, Anne Berger, Marc Van den Eynde, Franck Pagès, Alessandro Lugli, Jérôme Galon   +30 more
openaire   +4 more sources

Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer

Cancer Treatment and Research Communications, 2021
Background: This study aimed to deconvolve the levels of infiltrating immune cells in non-small cell lung cancer (NSCLC) and to identify specific gene co-expression modules associated with prognosis of NSCLC.
Xue-Tao Li, Jia-Tao Zhang, Hong-Hong Yan, Jian Su, Mei-Ling Cheng, Qi-Hui Sun, Wen-Zhao Zhong, Yi-Long Wu, Dr. Xu-Chao Zhang, Dr. Jun Hou   +9 more
doaj   +1 more source

Prognostic significance of immunoscore related markers in bladder cancer

BMC Urology, 2021
Abstract Background The significance of total and specific subpopulations of tumor-infiltrating lymphocytes (TILs) in cancer is now well-documented. In the present study, we investigated the relevance of CD3+, CD8 +, CD45RO +, and FOXP3 + TILs to the prognosis and survival of patients with bladder cancer and the disease ...
Ali Ariafar, Alireza Sanati, Simin Ahmadvand, Golsa Shekarkhar, Akbar Safaei, Zahra Shayan, Zahra Faghih   +6 more
openaire   +3 more sources

Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancerResearch in context

EBioMedicine, 2023
Summary: Background: Anti-PD-1 and PD-L1 antibodies (mAbs) are approved immunotherapy agents to treat metastatic non-small cell lung cancer (NSCLC) patients. Only a minority of patients responds to these treatments and biomarkers predicting response are
François Ghiringhelli, Frederic Bibeau, Laurent Greillier, Jean-David Fumet, Alis Ilie, Florence Monville, Caroline Laugé, Aurélie Catteau, Isabelle Boquet, Amine Majdi, Erwan Morgand, Youssef Oulkhouir, Nicolas Brandone, Julien Adam, Thomas Sbarrato, Alboukadel Kassambara, Jacques Fieschi, Stéphane Garcia, Anne Laure Lepage, Pascale Tomasini, Jérôme Galon   +20 more
doaj   +1 more source

Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patients

OncoImmunology, 2020
The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. Its evaluation in the primary tumor of patients with stages I/II/III colorectal cancer (CRC) has prognostic value that has been ...
Pamela Baldin, Marc Van den Eynde, Bernhard Mlecnik, Jérôme Galon   +3 more
doaj   +1 more source

Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer

Frontiers in Oncology, 2020
BackgroundTo date, no combined immunoscore has been evaluated for prognostic stratification of early stage non-small-cell lung cancer (NSCLC). The main goal of this study was to investigate the prognostic impact of programmed death ligand 1 (PD-L1 ...
Alice Boscolo, Francesco Fortarezza, Francesca Lunardi, Giovanni Comacchio, Loredana Urso, Stefano Frega, Jessica Menis, Jessica Menis, Laura Bonanno, Valentina Guarneri, Valentina Guarneri, Federico Rea, PierFranco Conte, PierFranco Conte, Fiorella Calabrese, Giulia Pasello   +15 more
doaj   +1 more source